Journal of Pediatric Health And Nutrition

Journal of Pediatric Health And Nutrition

Journal of Pediatric Health and Nutrition

Current Issue Volume No: 1 Issue No: 1

Letter Open Access Available online freely Peer Reviewed Citation

COVID-19: What we know

Article Type: Letter

1Department of Pediatrics, Ped Mind Institute (PMI), Gronau, Germany

Abstract

A concise overview synthesizes early knowledge on COVID‑19 in pediatrics, covering transmission, clinical spectrum, diagnostics, and prevention, and pointing to priorities for longitudinal study.

Author Contributions
Received 31 Mar 2020; Accepted 04 Apr 2020; Published 06 Apr 2020;

Academic Editor: Ibrahim Hassan Ibrahim, Prof. of Animal Physiology, Department of radioactive isotopes

Checked for plagiarism: Yes

Review by: Single-blind

Copyright ©  2020 Stefan Bittmann

License
Creative Commons License     This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing interests

The authors have declared that no competing interests exist.

Citation:

Stefan Bittmann (2020) COVID-19: What we know. Journal of Pediatric Health And Nutrition - 1(1):27-27. https://doi.org/10.14302/issn.2691-5014.jphn-20-3297

Download as RIS, BibTeX, Text (Include abstract )

DOI 10.14302/issn.2691-5014.jphn-20-3297

Letter

SARS-CoV-2 coronavirus infection outbreak has been reported in December 2019 in Wuhan, China (1-4). COVID 19 corona disease seems to be different from children and adults. The question is why? To date, there have been only few fatal in childhood, in complete difference to adults. Till 26 of March 2020, WHO registered 2401 deaths worldwide. A series and devastating new virus spreading at an extremely rapid pace all over the world. More than 100.000 infections were found in the US until the date of this publication.

What we know, COVID 19 could be a result of a similar coronavirus in bats, spreading exponential, one human transmitter infects 3 people, 3 infected patients infect themselves to nine, and so on. Chinese researchers floot their young research articles about COVID 19 to western journals. What we know, COVID-19 will kill many people, and, children. COVID 19 infects the lungs leading to severe crown pneumonia and later ARDS. What we know, that older patients with disabilities and underlying diseases like hypertension and diabetes are at greater risk for developing a fatal outcome in COVID-19. The search for drugs and research efforts in developing a vaccination is at high speed. COVID-19 binds with spike protein to the angiotensin-II receptor. Vaccination research focuses on inactivating spike protein and the binding domain. The receptor binding domain is well known. Research must concentrate intensively on blocking and inactivate the spike protein receptor domain of COVID-19. Drug theories think about blocking the angiotensin II receptor by Losartan or another angiotensin II blocker, that COVID 19 can’t bind to ACE2. What we know is that in some severe cases of Losartan treatment, the patient course was more fatal. At the University of Minnesota, a randomized trial was introduced on 16/03/2020 in 200 patients to prove the advantage of Losartan in the treatment of COVID-19 patients. Attempts to give children lopinavir/retinavir sirup was introduced in China few weeks after outbreak in Wuhan, in children. What we know, all given drugs, hydrocloroquin, Losartan, lopinavir/retinavir, antibody-rich plasma from survivors show, to date, no overwhelming therapeutical effect in COVID-19 patients. What we know is, that in children, a higher level of procalcitonin, a higher level of dimere and surprisingly, a higher level of creatine kinase MB is oenzyme was found, suggesting a myocardial potential. Research efforts in general are in childhood shoes are due to the extremely rapid spreading of this novel virus a challenge for the human being.

What we know, COVID-19 will change our lives, our world.

Cited by (26)

This article has been cited by 26 scholarly works according to:

OpenAlex 3 citations Semantic Scholar 23 citations

Citing Articles:

1.Genes Involved in miRNA Biogenesis Are Not Downregulated in SARS-CoV-2 Infection
N. Garnier, F. Sane, Layal Massara, F. Soncin, P. Gosset et al. - Viruses (2023) Semantic Scholar
2.Gaidai reliability method for long-term coronavirus modelling
O. Gaidai, P. Yan, Y. Xing, Jingxiang Xu, Yu Wu - F1000Research (2022) Semantic Scholar
3.Role of Wearable Sensing Technology to Manage Long COVID
Kamil Reza Khondakar, A. Kaushik - Biosensors (2022) Semantic Scholar
5.Low dose whole Lung Therapy for patients with SARS-CoV-2 disease (COVID-19) Pneumonitis
Pavel D. Pankov, M. K. Salpagarov, N. Yakovleva, Alexey V. Andronov, G. A. Baranov et al. - (2021) Semantic Scholar
7.Promoting Compliance to COVID-19 Vaccination in Military Units
David Segal, Yonatan Ilibman Arzi, M. Bez, Matan Cohen, Jacob Rotschield et al. - Military Medicine (2021) Semantic Scholar
8.Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis
Ya-jing Hou, Shuai Ge, Xiaowei Li, Cheng Wang, Huaizhen He et al. - Chemico-Biological Interactions (2021) Semantic Scholar
11.Can human overcome viral hijack-? Comprehensive review on COVID-19 in the view of diagnosis and mitigation across countries
Maheswari Nagendran, J. John, Kavithakani Annamalai, Muthu Iswarya Gandhi Sethuraman, Nirkayani Balamurugan et al. - Journal of Drug Delivery Science and Technology (2020) Semantic Scholar
14.Current Situation of Coronavirus Disease: (COVID-19) Review Article
Albaraa A Milibari - (2020) Semantic Scholar
15.Current trends and possible therapeutic options against COVID-19
Uzair Ahmed, U. Ashfaq, S. Khaliq, M. Qasim, S. Jahan et al. - Journal of Microbiology and Infectious Diseases (2020) Semantic Scholar
18.Is Antioxidant Therapy a Useful Complementary Measure for Covid-19 Treatment? An Algorithm for Its Application
M. Soto, V. Guarner-Lans, E. Soria-Castro, L. Manzano Pech, I. Pérez-Torres - Medicina (2020) Semantic Scholar
19.Measures to Limit COVID-19 Outbreak Effects Among Military Personnel: Preliminary Data
David Segal, Jacob Rotschield, Ran Ankory, S. Kutikov, Bian Moaddi et al. - Military Medicine (2020) Semantic Scholar
20.Medidas para Prevenir el COVID-19 en el Consultorio Dental
B. E. Falcón-Guerrero, Guido Sebastián Falcón-Pasapera - (2020) Semantic Scholar
21.Novel Coronavirus: Current Understanding of Clinical Features, Diagnosis, Pathogenesis, and Treatment Options
Mohammad Ridwane Mungroo, N. Khan, R. Siddiqui - Pathogens (2020) Semantic Scholar
22.Nutritional Support in Coronavirus 2019 Disease
E. Stachowska, M. Folwarski, D. Jamioł-Milc, D. Maciejewska, K. Skonieczna-Żydecka - Medicina (2020) Semantic Scholar
23.Pathological Findings and Management of COVID-19 Patients: A Brief Overview of Modern-day Pandemic
M. S. Mian, Laiba Razaq, Safeera Khan, N. Hussain, M. Razaq - Cureus (2020) Semantic Scholar
24.Prediction of Small Molecule Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus-2 RNA-dependent RNA Polymerase
Mohammed Ahmad, A. Dwivedy, R. Mariadasse, S. Tiwari, Deepsikha Kar et al. - ACS Omega (2020) Semantic Scholar
25.The COVID-19 Outbreak and Affected Countries Stock Markets Response
Haiyue Liu, Aqsa Manzoor, Cangyu Wang, Lei Zhang, Zaira Manzoor - International Journal of Environmental Research and Public Health (2020) Semantic Scholar
26.Transmission mode associated with coronavirus disease 2019: a review.
F. Vella, P. Senia, Manuela Ceccarelli, Ermanno Vitale, H. Maltezou et al. - European Review for Medical and Pharmacological Sciences (2020) Semantic Scholar